Photo of the week: ACRF Blood Cancer Therapeutics launch

The Australian Centre for Blood Diseases hosted a launch of the new Australian Cancer Research Foundation (ACRF) Blood Cancer Therapeutics Centre on 24 July 2018. The visitors from ACRF and the community had a tour of the new laboratory and centre, then listened to talks from the senior researchers and a patient who has already benefited from the research into improved treatments. Seen here, left to right, are Mr Russell Caplan (Director, ACRF), Kerry Strydom (Chief Operating Officer, ACRF), Mr Greg Camm (Director, ACRF), Victoria Bonsey (Philanthropy & Engagement Manager, ACRF), Professor Ian Brown (CEO, ACRF), Mr Gordon Wheaton (Wheaton Foundation donor), Professor Andrew Spencer (Group leader, ACBD and Head of the Malignant Haematology and Stem Cell Transplantation Service, The Alfred), Associate Professor Andrew Wei (Group Leader, ACBD and Head of leukaemia research, The Alfred). See more about the launch and the centre in this issue's story.

Australia’s first dedicated Blood Cancer Therapeutics Centre launched

The ACRF Blood Cancer Therapeutics Centre launch ceremony
held at the Alfred Medical Research and Education Precinct. 
L-R: Russell Caplan (ACRF), A/Prof Andrew Wei, Prof Andrew
Spencer and Greg Camm (ACRF)

The Alfred and Monash University have established a dedicated centre for Blood Cancer Therapeutics Research, thanks to a $1.2 million grant from the Australian Cancer Research Foundation (ACRF). The grant was awarded to a team of haematologists led by Associate Professor Andrew Wei, and Professors Andrew Spencer, David Curtis and Stephen Jane, and the centre was officially launched on Tuesday 24 July 2018.  

Australia’s first dedicated blood cancer research centre

Associate Professor Andrew Wei

The Alfred and Monash University are set to establish Australia’s first dedicated blood cancer research centre, thanks to a $1.2 million grant from the Australian Cancer Research Foundation (ACRF).

The ACRF Blood Cancer Therapeutics Centre, based at The Alfred, will be home to the latest technology available in blood cancer research and will enable researchers to dramatically improve outcomes for patients with blood cancer.